Renhe Pharmacy Co Ltd (000650) - Net Assets
Based on the latest financial reports, Renhe Pharmacy Co Ltd (000650) has net assets worth CN¥7.11 Billion CNY (≈ $1.04 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.93 Billion ≈ $1.16 Billion USD) and total liabilities (CN¥823.87 Million ≈ $120.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000650 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.11 Billion |
| % of Total Assets | 89.62% |
| Annual Growth Rate | 21.7% |
| 5-Year Change | 16.96% |
| 10-Year Change | 116.32% |
| Growth Volatility | 81.46 |
Renhe Pharmacy Co Ltd - Net Assets Trend (1993–2025)
This chart illustrates how Renhe Pharmacy Co Ltd's net assets have evolved over time, based on quarterly financial data. See 000650 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Renhe Pharmacy Co Ltd (1993–2025)
The table below shows the annual net assets of Renhe Pharmacy Co Ltd from 1993 to 2025. For live valuation and market cap data, see Renhe Pharmacy Co Ltd (000650) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.93 Billion ≈ $1.01 Billion |
+1.85% |
| 2024-12-31 | CN¥6.81 Billion ≈ $995.93 Million |
+2.28% |
| 2023-12-31 | CN¥6.65 Billion ≈ $973.76 Million |
+3.62% |
| 2022-12-31 | CN¥6.42 Billion ≈ $939.71 Million |
+8.35% |
| 2021-12-31 | CN¥5.93 Billion ≈ $867.29 Million |
+5.64% |
| 2020-12-31 | CN¥5.61 Billion ≈ $820.99 Million |
+28.92% |
| 2019-12-31 | CN¥4.35 Billion ≈ $636.83 Million |
+11.16% |
| 2018-12-31 | CN¥3.91 Billion ≈ $572.89 Million |
+12.74% |
| 2017-12-31 | CN¥3.47 Billion ≈ $508.13 Million |
+8.36% |
| 2016-12-31 | CN¥3.20 Billion ≈ $468.92 Million |
+23.21% |
| 2015-12-31 | CN¥2.60 Billion ≈ $380.59 Million |
+20.30% |
| 2014-12-31 | CN¥2.16 Billion ≈ $316.38 Million |
+11.51% |
| 2013-12-31 | CN¥1.94 Billion ≈ $283.72 Million |
+13.25% |
| 2012-12-31 | CN¥1.71 Billion ≈ $250.53 Million |
+49.90% |
| 2011-12-31 | CN¥1.14 Billion ≈ $167.13 Million |
+25.22% |
| 2010-12-31 | CN¥912.05 Million ≈ $133.46 Million |
+6.40% |
| 2009-12-31 | CN¥857.16 Million ≈ $125.43 Million |
+180.48% |
| 2008-12-31 | CN¥305.60 Million ≈ $44.72 Million |
+29.80% |
| 2007-12-31 | CN¥235.44 Million ≈ $34.45 Million |
+20.92% |
| 2006-12-31 | CN¥194.71 Million ≈ $28.49 Million |
+315.30% |
| 2005-12-31 | CN¥46.88 Million ≈ $6.86 Million |
-72.27% |
| 2004-12-31 | CN¥169.04 Million ≈ $24.74 Million |
-29.02% |
| 2003-12-31 | CN¥238.17 Million ≈ $34.85 Million |
-29.69% |
| 2002-12-31 | CN¥338.74 Million ≈ $49.57 Million |
+2.16% |
| 2001-12-31 | CN¥331.58 Million ≈ $48.52 Million |
-3.98% |
| 2000-12-31 | CN¥345.32 Million ≈ $50.53 Million |
+32.06% |
| 1999-12-31 | CN¥261.49 Million ≈ $38.26 Million |
+11.86% |
| 1998-12-31 | CN¥233.76 Million ≈ $34.21 Million |
+46.61% |
| 1997-12-31 | CN¥159.44 Million ≈ $23.33 Million |
+11.45% |
| 1996-12-31 | CN¥143.07 Million ≈ $20.94 Million |
+179.01% |
| 1995-12-31 | CN¥51.28 Million ≈ $7.50 Million |
+5.40% |
| 1994-12-31 | CN¥48.65 Million ≈ $7.12 Million |
+276.53% |
| 1993-12-31 | CN¥12.92 Million ≈ $1.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Renhe Pharmacy Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 368179768776.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.68 Billion | 58.30% |
| Other Components | CN¥2.63 Billion | 41.70% |
| Total Equity | CN¥6.32 Billion | 100.00% |
Renhe Pharmacy Co Ltd Competitors by Market Cap
The table below lists competitors of Renhe Pharmacy Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gunkul Engineering Public Company Limited
BK:GUNKUL
|
$1.05 Billion |
|
PT Arkora Hydro Tbk
JK:ARKO
|
$1.05 Billion |
|
Hangzhou Jingye Intelligent Technology Co. Ltd. A
SHG:688290
|
$1.05 Billion |
|
Wuhan Xianglong Power Industry Co Ltd
SHG:600769
|
$1.05 Billion |
|
SHANGHAI FU. MIC.H YC-10
F:FUD
|
$1.05 Billion |
|
Dorian LPG Ltd
NYSE:LPG
|
$1.05 Billion |
|
Guangdong Macro Co Ltd
SHE:000533
|
$1.05 Billion |
|
Deluxe Corporation
NYSE:DLX
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Renhe Pharmacy Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,173,659,007 to 6,315,571,808, a change of 141,912,801 (2.3%).
- Net income of 393,208,101 contributed positively to equity growth.
- Dividend payments of 210,482,943 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥393.21 Million | +6.23% |
| Dividends Paid | CN¥210.48 Million | -3.33% |
| Other Changes | CN¥-40.81 Million | -0.65% |
| Total Change | CN¥- | 2.30% |
Book Value vs Market Value Analysis
This analysis compares Renhe Pharmacy Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 364.50x to 1.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥0.01 | CN¥5.13 | x |
| 1994-12-31 | CN¥0.05 | CN¥5.13 | x |
| 1995-12-31 | CN¥0.06 | CN¥5.13 | x |
| 1996-12-31 | CN¥0.16 | CN¥5.13 | x |
| 1997-12-31 | CN¥0.17 | CN¥5.13 | x |
| 1998-12-31 | CN¥0.25 | CN¥5.13 | x |
| 1999-12-31 | CN¥0.28 | CN¥5.13 | x |
| 2000-12-31 | CN¥0.38 | CN¥5.13 | x |
| 2001-12-31 | CN¥0.36 | CN¥5.13 | x |
| 2002-12-31 | CN¥0.37 | CN¥5.13 | x |
| 2003-12-31 | CN¥0.26 | CN¥5.13 | x |
| 2004-12-31 | CN¥0.18 | CN¥5.13 | x |
| 2005-12-31 | CN¥0.05 | CN¥5.13 | x |
| 2006-12-31 | CN¥0.21 | CN¥5.13 | x |
| 2007-12-31 | CN¥0.26 | CN¥5.13 | x |
| 2008-12-31 | CN¥0.33 | CN¥5.13 | x |
| 2009-12-31 | CN¥0.83 | CN¥5.13 | x |
| 2010-12-31 | CN¥1.10 | CN¥5.13 | x |
| 2011-12-31 | CN¥0.94 | CN¥5.13 | x |
| 2012-12-31 | CN¥1.32 | CN¥5.13 | x |
| 2013-12-31 | CN¥1.50 | CN¥5.13 | x |
| 2014-12-31 | CN¥1.62 | CN¥5.13 | x |
| 2015-12-31 | CN¥1.95 | CN¥5.13 | x |
| 2016-12-31 | CN¥2.22 | CN¥5.13 | x |
| 2017-12-31 | CN¥2.45 | CN¥5.13 | x |
| 2018-12-31 | CN¥2.75 | CN¥5.13 | x |
| 2019-12-31 | CN¥3.07 | CN¥5.13 | x |
| 2020-12-31 | CN¥4.02 | CN¥5.13 | x |
| 2021-12-31 | CN¥3.78 | CN¥5.13 | x |
| 2022-12-31 | CN¥4.10 | CN¥5.13 | x |
| 2023-12-31 | CN¥4.33 | CN¥5.13 | x |
| 2024-12-31 | CN¥4.46 | CN¥5.13 | x |
| 2025-12-31 | CN¥4.51 | CN¥5.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Renhe Pharmacy Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.23%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.12%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.22x
- Recent ROE (6.23%) is above the historical average (6.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 99.11% | 10.14% | 0.97x | 10.04x | CN¥11.51 Million |
| 1994 | 27.66% | 10.18% | 0.77x | 3.55x | CN¥8.59 Million |
| 1995 | 34.15% | 10.89% | 0.94x | 3.33x | CN¥12.38 Million |
| 1996 | 10.47% | 8.84% | 0.63x | 1.89x | CN¥672.06K |
| 1997 | 10.27% | 12.02% | 0.49x | 1.74x | CN¥431.12K |
| 1998 | 12.11% | 14.69% | 0.54x | 1.54x | CN¥4.93 Million |
| 1999 | 10.60% | 11.75% | 0.50x | 1.82x | CN¥1.58 Million |
| 2000 | 6.31% | 9.23% | 0.36x | 1.89x | CN¥-12.74 Million |
| 2001 | -4.37% | -6.43% | 0.32x | 2.15x | CN¥-47.64 Million |
| 2002 | 2.59% | 3.97% | 0.29x | 2.24x | CN¥-25.11 Million |
| 2003 | -42.19% | -35.68% | 0.41x | 2.85x | CN¥-124.30 Million |
| 2004 | -37.22% | -22.44% | 0.47x | 3.55x | CN¥-79.82 Million |
| 2005 | -277.16% | -48.64% | 0.59x | 9.73x | CN¥-134.63 Million |
| 2006 | 66.92% | 522.39% | 0.09x | 1.40x | CN¥110.83 Million |
| 2007 | 16.64% | 5.03% | 2.52x | 1.31x | CN¥15.63 Million |
| 2008 | 22.96% | 8.01% | 2.00x | 1.43x | CN¥39.60 Million |
| 2009 | 19.70% | 17.17% | 0.93x | 1.24x | CN¥83.08 Million |
| 2010 | 25.12% | 16.06% | 0.92x | 1.69x | CN¥132.13 Million |
| 2011 | 26.89% | 13.71% | 1.37x | 1.43x | CN¥188.66 Million |
| 2012 | 15.76% | 12.24% | 1.00x | 1.29x | CN¥93.39 Million |
| 2013 | 10.63% | 10.79% | 0.77x | 1.28x | CN¥11.54 Million |
| 2014 | 14.80% | 13.35% | 0.87x | 1.28x | CN¥97.61 Million |
| 2015 | 16.38% | 15.50% | 0.80x | 1.32x | CN¥152.40 Million |
| 2016 | 13.53% | 10.44% | 0.92x | 1.40x | CN¥97.20 Million |
| 2017 | 12.64% | 9.89% | 0.92x | 1.39x | CN¥79.37 Million |
| 2018 | 14.93% | 11.50% | 0.95x | 1.36x | CN¥167.31 Million |
| 2019 | 14.13% | 11.74% | 0.92x | 1.31x | CN¥157.27 Million |
| 2020 | 11.44% | 13.56% | 0.68x | 1.24x | CN¥72.89 Million |
| 2021 | 12.58% | 13.47% | 0.71x | 1.31x | CN¥136.30 Million |
| 2022 | 10.01% | 11.15% | 0.68x | 1.33x | CN¥351.25K |
| 2023 | 9.47% | 11.27% | 0.68x | 1.24x | CN¥-32.05 Million |
| 2024 | 7.81% | 11.83% | 0.54x | 1.21x | CN¥-135.45 Million |
| 2025 | 6.23% | 11.12% | 0.46x | 1.22x | CN¥-238.35 Million |
Industry Comparison
This section compares Renhe Pharmacy Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Renhe Pharmacy Co Ltd (000650) | CN¥7.11 Billion | 99.11% | 0.12x | $1.05 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Renhe Pharmacy Co Ltd
Renhe Pharmacy Co.,Ltd produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, external lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in … Read more